t
Diaceutics PLC announced on 2 September 2024 the appointment of Canaccord Genuity Limited. Canaccord Genuity Limited will serve as the Company's Nominated Adviser and Broker, with immediate effect.
| Date | 2 Sept 2024 |
| Time | 07:00:10 |
| Category | Corporate updates |
| ID | 3993C |
Appointment of Nominated Adviser and Broker
Belfast and London, 2 September 2024 - Diaceutics PLC (AIM: DXRX), a leading technology and solutions provider to the pharma and biotech industry is pleased to announce the appointment of Canaccord Genuity Limited as the Company's Nominated Adviser and Broker, with immediate effect.
Enquiries:
|
Diaceutics PLC |
|
|
Ryan Keeling, Chief Executive Officer Nick Roberts, Chief Financial Officer |
Tel: +44 (0)28 9040 6500
|
|
Canaccord Genuity Limited (Nomad & Broker) |
Tel: +44 (0)20 7523 8000 |
|
Simon Bridges, Andrew Potts, Harry Rees |
|
|
Alma Strategic Communications |
Tel: +44(0)20 3405 0205 |
|
Caroline Forde, Kinvara Verdon
|
About Diaceutics
At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome.
We provide the world's leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX - The Diagnostics Network ®.